Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in atopic dermatitis. The OX40-OX40L interaction (2 co-stimulatory immune checkpoint molecules) plays a central role in the pathogenesis of atopic dermatitis. In this educational program, these experts review the evidence for the emerging role of OX40-OX40L axis inhibition in the treatment of patients with atopic dermatitis.
This educational activity is an archive of the live symposium held on June 7, 2025.
Target Audience
This educational activity is designed for dermatologists, allergists, immunologists, pediatricians, primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in the diagnosis, management, and treatment of patients with atopic dermatitis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the clinical rationale for the development of OX40 & OX40 ligand inhibitor–targeted therapies in the treatment of moderate-to-severe AD
- Analyze clinical trial efficacy and safety data for current and novel emerging OX40 & OX40 ligand inhibitor–targeted therapies in the treatment of moderate-to-severe AD
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here